Quince Therapeutics, Inc.
For the period ended Jun 30, 2025. Filed Aug 11, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 11, 2025
QNCX$31.73+8.1%Stored close · as of Oct 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Quince Therapeutics, Inc. | ||
| Date: August 11, 2025 | By: | /s/ Dirk Thye |
|---|---|---|
| Dirk Thye | ||
| Chief Executive Officer and Chief Medical Officer | ||
| (Principal Executive Officer) | ||
| Date: August 11, 2025 | By: | /s/ Brendan Hannah |
| Brendan Hannah | ||
| Chief Business Officer, Chief Operating Officer, and Chief Compliance Officer | ||
| (Principal Financial Officer) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.